Endocrine Abstracts

Background and Aim: To study the cardioprotective effects of empagliflozin and vildagliptin in patients with diabetes type 2.

Method: 90 patients with type 2 diabetes were randomized using a random number generator into 3 groups, depending on the antihyperglycemic therapy prescribed for the next 6 months: the group that continued to receive gliclazide and metformin, the group in addition to gliclazide and metformin received vildagliptin at a dose of 100 mg/day, the group in addition to gliclazide and metformin received empaglilflozin at a dose of 25 mg/day.

Results: Empagliflozin therapy was accompanied by regression of the left ventricular mass index (118.00 [116.00; 121.00] g/m²) vs 121.00 [118.00; 122.00] g/m²) and a decrease of the natriuretic peptide (proBNP) (23.50 [16.70; 33.30] pg/ml vs 31.00 [24.30; 46.20] pg/ml (p <0.05).

Conclusion: SGLT2 inhibition by empagliflozin has a complex and multifunctional effect on the body that can effectively influence cardiovascular outcomes.